Xiaoshan Min
Xiaoshan Min has a total of 65 co-authors. Here are the top co-authors by number of shared publications:
- Ching-Shin Huang
Affiliation BioMedicine Design, Pfizer, Inc., Cambridge, Massachusetts, United States of America
3 shared publications Zhulun Wang
Department of Therapeutics Discovery, Amgen Research, Amgen Inc., South San Francisco, USA
3 shared publications- Zhulun Wang
Amgen Inc., 1120 Veterans Boulevard, South San Francisco, CA 94080, USA
3 shared publications - Christina M. Abbott
Department of Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA
2 shared publications - Clarence Hale
Amgen Research, Department of Cardiometabolic Disorders, Amgen Inc., One Amgen Center Dr., Thousand Oaks, CA 91320, USA
2 shared publications Joanne Lin
Department of Therapeutic Discovery, Amgen Research, Thousand Oaks, CA, USA
2 shared publications
Latest Publications
- Open Access
- 5 May 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-9
Cryo-EM structure of ABCG5/G8 in complex with modulating antibodies
The heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8 mediates the excretion of sterols from liver and intestine, playing a critical role in cholesterol homeostasis. Here, we present the cryo-EM structure of ABCG5/G8 in complex with the Fab fragments from two monoclonal antibodies at 3.3Å resolution. The high-resolution structure reveals a unique dimer interface between the nucleotide-binding domains (NBD) of opposing transporters, consisting of an ordered network of salt bridges between the conserved NPXDFXXD motif and serving as a pivot point that may be important for the transport cycle. While mAb 11F4 increases the ATPase activity potentially by stabilization of the NBD dimer formation, mAb 2E10 inhibits ATP hydrolysis, likely by restricting the relative movement between the RecA and helical domain of ABCG8 NBD. Our study not only provides insights into the structural elements important for the transport cycle but also reveals novel epitopes for potential therapeutic interventions.
- 5 May 2021
- Published by Springer Nature in Communications Biology
- Vol. 4 (1) , 1-9
Open AccessCryo-EM structure of ABCG5/G8 in complex with modulating antibodies
The heterodimer of ATP-binding cassette transporter ABCG5 and ABCG8 mediates the excretion of sterols from liver and intestine, playing a critical role in cholesterol homeostasis. Here, we present the cryo-EM structure of ABCG5/G8 in complex with the Fab fragments from two monoclonal antibodies at 3.3Å resolution. The high-resolution structure reveals a unique dimer interface between the nucleotide-binding domains (NBD) of opposing transporters, consisting of an ordered network of salt bridges between the conserved NPXDFXXD motif and serving as a pivot point that may be important for the transport cycle. While mAb 11F4 increases the ATPase activity potentially by stabilization of the NBD dimer formation, mAb 2E10 inhibits ATP hydrolysis, likely by restricting the relative movement between the RecA and helical domain of ABCG8 NBD. Our study not only provides insights into the structural elements important for the transport cycle but also reveals novel epitopes for potential therapeutic interventions.
- Open Access
- 17 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (25) , eabb1989
Cryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
Details of intestinal sterol absorption and inhibition by cholesterol-lowering drug are uncovered in new protein structures.
- 17 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 6 (25) , eabb1989
Open AccessCryo-EM structures of NPC1L1 reveal mechanisms of cholesterol transport and ezetimibe inhibition
Details of intestinal sterol absorption and inhibition by cholesterol-lowering drug are uncovered in new protein structures.
- Open Access
- 12 January 2020
- Published by Taylor & Francis in mAbs
- Vol. 12 (1) , 1710047
Molecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone involved in regulating glucose and lipid metabolism. GIP receptor (GIPR) antagonism is believed to offer therapeutic potential for various metabolic diseases. Pharmacological intervention of GIPR, however, has limited success due to lack of effective antagonistic reagents. Previously we reported the discovery of two mouse anti-murine GIPR monoclonal antibodies (mAbs) with distinctive properties in rodent models. Here, we report the detailed structural and biochemical characterization of these two antibodies, mAb1 and mAb2. In vitro and in vivo characterizations demonstrated mAb2 is a full GIPR antagonistic antibody and mAb1 is a non-neutralizing GIPR binder. To understand the molecular basis of these two antibodies, we determined the co-crystal structures of GIPR extracellular domain in complex with mAb1 and with mAb2 at resolutions of 2.1 and 2.6 Å, respectively. While the non-neutralizing mAb1 binds to GIPR without competing with the ligand peptide, mAb2 not only partially occludes the ligand peptide binding, but also recognizes the GIPR C-terminal stalk region in a helical conformation that acts as a molecular mimic of the ligand peptide and locks GIPR in a novel auto-inhibited state. Furthermore, administration of mAb2 in diet-induced obesity mice for 7 weeks leads to both reduction in body weight gain and improvement of metabolic profiles. In contrast, mAb1 has no effect on body weight or other metabolic improvement. Together, our studies reveal the unique molecular mechanism of action underlying the superior antagonistic activity of mAb2 and signify the promising therapeutic potential of effective GIPR antagonism for the treatment of metabolic disorders.
- 12 January 2020
- Published by Taylor & Francis in mAbs
- Vol. 12 (1) , 1710047
Open AccessMolecular mechanism of an antagonistic antibody against glucose-dependent insulinotropic polypeptide receptor
Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone involved in regulating glucose and lipid metabolism. GIP receptor (GIPR) antagonism is believed to offer therapeutic potential for various metabolic diseases. Pharmacological intervention of GIPR, however, has limited success due to lack of effective antagonistic reagents. Previously we reported the discovery of two mouse anti-murine GIPR monoclonal antibodies (mAbs) with distinctive properties in rodent models. Here, we report the detailed structural and biochemical characterization of these two antibodies, mAb1 and mAb2. In vitro and in vivo characterizations demonstrated mAb2 is a full GIPR antagonistic antibody and mAb1 is a non-neutralizing GIPR binder. To understand the molecular basis of these two antibodies, we determined the co-crystal structures of GIPR extracellular domain in complex with mAb1 and with mAb2 at resolutions of 2.1 and 2.6 Å, respectively. While the non-neutralizing mAb1 binds to GIPR without competing with the ligand peptide, mAb2 not only partially occludes the ligand peptide binding, but also recognizes the GIPR C-terminal stalk region in a helical conformation that acts as a molecular mimic of the ligand peptide and locks GIPR in a novel auto-inhibited state. Furthermore, administration of mAb2 in diet-induced obesity mice for 7 weeks leads to both reduction in body weight gain and improvement of metabolic profiles. In contrast, mAb1 has no effect on body weight or other metabolic improvement. Together, our studies reveal the unique molecular mechanism of action underlying the superior antagonistic activity of mAb2 and signify the promising therapeutic potential of effective GIPR antagonism for the treatment of metabolic disorders.
- 19 December 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (472)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Antibody antagonists of the insulinotropic receptor GIPR prevent weight gain in obese animal models, and the effect is enhanced by GLP-1R agonists.
- 19 December 2018
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 10 (472)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Antibody antagonists of the insulinotropic receptor GIPR prevent weight gain in obese animal models, and the effect is enhanced by GLP-1R agonists.
- Open Access
- 1 September 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (38) , 14678-14688
Agonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions
- 1 September 2018
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 293 (38) , 14678-14688
Open AccessAgonistic β-Klotho antibody mimics fibroblast growth factor 21 (FGF21) functions
- 18 October 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (412)
Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys
Engineered long-acting GDF15-Fc fusion molecules reduce food intake and body weight and improve metabolic profiles in animal models of obesity.
- 18 October 2017
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 9 (412)
Long-acting MIC-1/GDF15 molecules to treat obesity: Evidence from mice to monkeys
Engineered long-acting GDF15-Fc fusion molecules reduce food intake and body weight and improve metabolic profiles in animal models of obesity.